Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Regeneron cuts White House pricing deal, offers new gene therapy for free
  • Policy / Pricing

Regeneron cuts White House pricing deal, offers new gene therapy for free

Pharmaceutical Technology

This White House deal will see Regeneron offer all its new medicines at "MFN prices", while providing Otarmeni for free to eligible patients.

Policy / PricingGene Therapy PlatformRead full story

pharminent April 24, 2026 (Last updated: April 24, 2026)

Pharmaceutical Technology

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

Policy / PricingGene Therapy PlatformRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Cumberland to sell drug portfolio to Apotex for $100m
Next: Cardiometabolic trials: Using expertise to turn complexity into robust results

Related Stories

  • Policy / Pricing

Germany approves healthcare costs overhaul despite significant pharma opposition

pharminent July 13, 2026
  • Policy / Pricing

Decoding Medicare Advantage Coding Intensity

pharminent July 1, 2026
  • Policy / Pricing

UK partners with Eli Lilly on obesity plan

pharminent June 29, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.